

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols informs that it has closed the transaction to acquire 7 U.S. based plasma donation centers from Kedplasma, LLC. (a company belonging to the Kedrion Group) for a total purchase price of USD 55.2 million. The 7 centers acquired are authorized by the U.S. Food and Drug Administration (FDA) and European health authorities and collect approximately 240,000 liters of plasma. Grifols will have immediate access to the plasma obtained from these centers.

This acquisition reflects Grifols' commitment to enlarge its plasma supply through organic and inorganic growth.

Since January 2021, Grifols' efforts to accelerate the execution of its strategic expansion plan have enabled it to immediately leverage an additional approximately 1.4 million liters of plasma per year. At the same time, the company continues its efforts to open new centers.

The transaction is financed from Grifols' own resources.

This acquisition is aligned with Grifols' global expansion and plasma-supply diversification strategy, with 296 plasma centers in the U.S. following this transaction and 55 in Europe across Germany, Austria and, recently Hungary. Likewise, Grifols remains committed to increasing its supply of plasma and plasma-derived therapies to ensure patients continue to receive the treatments and healthcare they need.

In Barcelona, on 7 April 2021

Nuria Martín Barnés
Secretary to the Board of Directors